StockNews.com started coverage on shares of Aclaris Therapeutics (NASDAQ:ACRS – Free Report) in a report issued on Thursday morning. The brokerage issued a sell rating on the biotechnology company’s stock. Separately, HC Wainwright reissued a buy rating and set a $43.00 price objective on shares of Aclaris Therapeutics in a report on Tuesday, August 8th. […]
StockNews.com started coverage on shares of Aclaris Therapeutics (NASDAQ:ACRS – Free Report) in a report issued on Thursday. The brokerage issued a sell rating on the biotechnology company’s stock. Separately, HC Wainwright reiterated a buy rating and set a $43.00 target price on shares of Aclaris Therapeutics in a research note on Tuesday, August 8th. […]
Aclaris Therapeutics (NASDAQ:ACRS) Earns Sell Rating from Analysts at StockNews com themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Aclaris Therapeutics (NASDAQ:ACRS) Coverage Initiated by Analysts at StockNews com theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Free Report) – Cantor Fitzgerald increased their FY2023 earnings per share estimates for Aclaris Therapeutics in a research note issued on Tuesday, August 8th. Cantor Fitzgerald analyst L. Chen now expects that the biotechnology company will post earnings per share of ($1.86) for the year, up from their prior forecast […]